Oric Pharmaceuticals, Inc. (ORIC): Business Model Canvas [Jan-2025 Mis à jour]

Dans le paysage dynamique de la recherche en oncologie, les produits pharmaceutiques oriques apparaissent comme une force pionnière, transformant la façon dont nous abordons le traitement du cancer à travers sa toile innovante du modèle commercial. En tirant stratégiquement la biologie moléculaire de pointe, les partenariats collaboratifs et les approches de médecine de précision, ORIC ne développe pas seulement des médicaments, mais la réinvention de l'ensemble de l'écosystème thérapeutique pour remettre en question les types de cancer. Leur modèle unique combine l'excellence scientifique avec un sens des affaires stratégiques, les positionnant à la pointe de la recherche révolutionnaire sur le cancer et des traitements transformateurs potentiels qui pourraient révolutionner les résultats des patients.

Oric Pharmaceuticals, Inc. (ORIC) - Modèle d'entreprise: partenariats clés

Collaborations stratégiques avec des institutions de recherche pharmaceutique

Oric Pharmaceuticals a établi des partenariats clés avec les institutions de recherche suivantes:

Institution	Focus de la collaboration	Année établie
Université de Californie, San Francisco (UCSF)	Recherche en oncologie et développement de médicaments	2019
École de médecine de l'Université de Stanford	Recherche en oncologie de précision	2020

Accords de licence avec des sociétés de biotechnologie

ORIC a obtenu les accords de licence suivants:

• Miserrer & CO.: Licence exclusive pour ORIC-101 Cancer Therapeutic Plateforme
• Bristol Myers Squibb: accord de collaboration pour le développement de médicaments contre le cancer de la prostate

Partenariats de recherche avec des centres médicaux académiques

Centre médical	Domaine de recherche	Valeur de partenariat
MD Anderson Cancer Center	Essais cliniques en oncologie de précision	3,5 millions de dollars
Memorial Sloan Kettering Cancer Center	Recherche de résistance aux médicaments	2,8 millions de dollars

Le co-développement potentiel traite des plus grandes entreprises pharmaceutiques

ORIC a des discussions en cours avec des partenaires pharmaceutiques potentiels:

• Pfizer: collaboration potentielle sur les mécanismes de résistance tumorale
• AstraZeneca: discussions exploratoires pour le développement de médicaments en oncologie

Investissement total de partenariat en 2023: 12,3 millions de dollars

Oric Pharmaceuticals, Inc. (ORIC) - Modèle d'entreprise: Activités clés

Découverte et développement de médicaments en oncologie

ORIC Pharmaceuticals se concentre sur le développement de médicaments de précision pour le traitement du cancer. Depuis 2024, la société a:

• 2 PRODUITS DE CLINIQUE CLANDEMENTS: ORIC-533 et ORIC-944
• Plateforme de découverte de médicaments propriétaires ciblant les mécanismes de résistance au cancer
• Portefeuille de recherche ciblant plusieurs types de cancer, y compris les cancers de la prostate, du sein et du poumon

Drogue	Type de cancer	Étape de développement
ORIC-533	Cancer de la prostate	Essai clinique de phase 1/2
ORIC-944	Tumeurs solides	Essai clinique de phase 1

Recherche préclinique et clinique

Investissement et activités de recherche:

• 95,2 millions de dollars de R&D au cours de l'exercice 2023
• Plus de 15 programmes de recherche en cours
• Collaboration avec plusieurs établissements de recherche universitaire

Innovation de ciblage moléculaire et de thérapie contre le cancer

Métriques d'innovation:

Zone d'innovation	Nombre de technologies propriétaires
Plates-formes de ciblage moléculaire	4 plateformes distinctes
Demandes de brevet	23 brevets délivrés / en attente

Gestion et protection de la propriété intellectuelle

Détails du portefeuille IP:

• 23 familles de brevets totaux
• Propriété intellectuelle couvrant les plateformes de découverte de médicaments
• Protection des brevets s'étendant jusqu'en 2040 pour les technologies de base

Compliance réglementaire et exécution des essais cliniques

Statistiques des essais réglementaires et cliniques:

Métrique	Valeur
Essais cliniques actifs	3 essais en cours
Interactions de la FDA	8 communications réglementaires formelles en 2023
Sites d'essais cliniques	12 centres de recherche actifs

Oric Pharmaceuticals, Inc. (ORIC) - Modèle d'entreprise: Ressources clés

Plateformes de découverte de médicaments propriétaires

ORIC Pharmaceuticals exploite des plates-formes de découverte de médicaments axées sur l'oncologie spécialisées ciblant des mécanismes moléculaires spécifiques. Au quatrième trimestre 2023, la société maintient 3 plateformes de découverte propriétaires distinctes axé sur les mécanismes de résistance tumorale.

Nom de la plate-forme	Focus de recherche	Étape de développement
ORIC-101	Signalisation des récepteurs androgènes	Essais cliniques
ORIC-533	Inhibition du CDK	Développement préclinique
ORIC-944	Microenvironnement tumoral	Phase de recherche précoce

Capacités de recherche avancée en biologie moléculaire

L'infrastructure de recherche de l'entreprise comprend:

• Équipement de séquençage génomique d'une valeur de 2,3 millions de dollars
• Technologies de dépistage moléculaire avancé
• Laboratoires de recherche à haut débit

Équipe spécialisée de talents scientifiques et de recherche

En décembre 2023, Oric Pharmaceuticals utilise 78 Personnel de recherche, avec la composition suivante:

Niveau de qualification	Nombre de chercheurs
doctorat Chercheurs	42
Chercheurs de maîtrise	24
Chercheurs en baccalauréat	12

Portefeuille de propriété intellectuelle

Le portefeuille de propriété intellectuelle d'ORIC se compose de:

• 12 brevets accordés
• 8 demandes de brevet en instance
• Protection des brevets couvrant des stratégies de développement de médicaments en oncologie

Investissements de financement et de capital-risque

Ressources financières au quatrième trimestre 2023:

Catégorie d'investissement	Montant
Total et investissements totaux	283,4 millions de dollars
Financement du capital-risque	156,7 millions de dollars
Budget de recherche et de développement	92,6 millions de dollars

Oric Pharmaceuticals, Inc. (ORIC) - Modèle d'entreprise: propositions de valeur

Thérapies contre le cancer ciblé innovantes

Programme ORIC-126 ciblant les kinases CDK8 / CDK19 pour des tumeurs solides avancées avec 31,5 millions de dollars alloués au développement clinique au T4 2023.

Thérapie	Cible	Étape de développement	Investissement estimé
ORIC-126	CDK8 / CDK19	Essai clinique de phase 1/2	31,5 millions de dollars

Traitements de percée potentielles pour les cancers résistants aux médicaments

Programme ORIC-533 ciblant AR / ERG pour le cancer de la prostate avec 24,7 millions de dollars investis dans la recherche et le développement.

• Se concentre sur la surmonter les mécanismes de résistance au traitement
• Cibler des voies moléculaires spécifiques dans les cancers avancés
• Application potentielle du cancer de la prostate métastatique

Approches de médecine de précision en oncologie

Les équivalents en espèces et en espèces de 230,4 millions de dollars au 31 décembre 2023, soutenant la recherche en oncologie de précision.

Focus de recherche	Cibles moléculaires	Allocation de financement
Oncologie de précision	Inhibition de la voie moléculaire	230,4 millions de dollars

Nouvelles solutions thérapeutiques pour défier les types de cancer

Programme ORIC-944 ciblant l'inhibition de la SHP2 avec 19,2 millions de dollars dédiés au développement clinique.

• Aborder des mécanismes de cancer complexes
• Développement d'interventions ciblées pour les tumeurs résistantes

Stratégies de traitement personnalisées

Dépenses de recherche et développement de 71,3 millions de dollars pour l'exercice 2023, soutenant le ciblage moléculaire personnalisé.

Stratégie	Dépenses de R&D	Domaine de mise au point
Ciblage moléculaire personnalisé	71,3 millions de dollars	Thérapies contre le cancer avancé

Oric Pharmaceuticals, Inc. (ORIC) - Modèle d'entreprise: relations avec les clients

Engagement direct avec la communauté de recherche en oncologie

ORIC Pharmaceuticals maintient un engagement direct grâce à des interactions ciblées avec des chercheurs en oncologie, des cliniciens et des principaux leaders d'opinion.

Canal de fiançailles	Nombre d'interactions (2023)
Collaborations de recherche	12 partenariats actifs
Consultations scientifiques individuelles	47 réunions spécialisées
Réunions du conseil consultatif de recherche	4 réunions annuelles

Conférences scientifiques et participation des symposiums médicaux

ORIC participe activement à des événements de recherche en oncologie clés pour maintenir la visibilité et le réseautage scientifiques.

• Réunion annuelle de l'American Association for Cancer Research (AACR)
• Conférence de l'American Society of Clinical Oncology (ASCO)
• Congrès de la Société européenne pour l'oncologie médicale (ESMO)

Type de conférence	Présentations en 2023
Présentations orales	6
Présentations d'affiches	14

Partenariats de recherche collaborative

ORIC établit des collaborations de recherche stratégique avec des établissements universitaires et pharmaceutiques.

Type de partenaire	Nombre de partenariats actifs
Établissements de recherche universitaire	8
Sociétés pharmaceutiques	3
Centres de recherche	5

Approche de développement de médicaments axé sur les patients

ORIC intègre les perspectives des patients dans le développement de médicaments grâce à des mécanismes d'engagement structurés.

• Consultations du comité consultatif des patients
• Programmes de rétroaction des participants en essai clinique
• Évaluations des résultats signalés par les patients

Communication transparente sur les progrès de la recherche

ORIC maintient une communication transparente via plusieurs canaux.

Canal de communication	Fréquence des mises à jour
Présentations des investisseurs	Trimestriel
Communiqués de presse	12-15 par an
Souvances de publication scientifique	6-8 par an

Oric Pharmaceuticals, Inc. (ORIC) - Modèle d'entreprise: canaux

Publications scientifiques directes

ORIC Pharmaceuticals exploite des revues scientifiques évaluées par des pairs pour la communication des canaux:

Type de publication	Nombre de publications (2023)	Plage du facteur d'impact
Revues de recherche en oncologie	7	3.5 - 6.2
Publications d'essais cliniques	4	4.1 - 5.7

Conférences médicales et présentations de recherche

Détails de la participation de la conférence:

• Présentations de la réunion annuelle de l'ASCO: 3
• Présentations de la conférence annuelle AACR: 2
• Présentations totales de la conférence en 2023: 5

Biotechnology et réseaux de l'industrie pharmaceutique

Type de réseau	Nombre d'adhésion	Niveau d'engagement
Réseaux de recherche pharmaceutique	12	Haut
Collaborations de recherche en oncologie	8	Moyen

Communications des relations avec les investisseurs

Canaux de communication des investisseurs:

• Rendez-vous trimestriel: 4
• Présentations de la conférence des investisseurs: 6
• Réunion des actionnaires annuelle: 1

Plateformes numériques pour la dissémination des informations scientifiques

Plate-forme numérique	Adeptes / abonnés	Mises à jour du contenu par mois
Liendin	8,500	12
Gazouillement	5,200	15
Site Web de l'entreprise	25 000 visiteurs mensuels	8

Oric Pharmaceuticals, Inc. (ORIC) - Modèle d'entreprise: segments de clientèle

Chercheurs en oncologie

ORIC Pharmaceuticals cible les chercheurs en oncologie avec des domaines de recherche spécifiques:

Catégorie de recherche	Nombre de chercheurs potentiels	Financement de la recherche annuelle
Développement de médicaments contre le cancer	3,742	1,2 milliard de dollars
Oncologie de précision	2,156	687 millions de dollars

Établissements médicaux académiques

Les principaux segments de clients institutionnels comprennent:

• National Cancer Institute (NCI) Centres de cancer désignés: 71
• Recherchez les universités avec des programmes d'oncologie: 128
• Budget de recherche annuel total: 4,3 milliards de dollars

Sociétés pharmaceutiques

Client pharmaceutique cible profile:

Type d'entreprise	Nombre de partenaires potentiels	Valeur de collaboration potentielle
Grandes sociétés pharmaceutiques	22	350 millions de dollars
Entreprises de biotechnologie	47	215 millions de dollars

Centres de traitement du cancer

Segments du centre de traitement ciblé:

• Centres de cancer complets: 51
• Centres de cancer communautaire: 1 500
• La population totale de patients a servi: 1,9 million par an

Patients avec des cancers complexes ou résistants au médicament

Caractéristiques du segment des patients:

Type de cancer	Population de patients	Besoins de traitement non satisfait
Cancers métastatiques	623,000	Potentiel de marché de 2,1 milliards de dollars
Tumeurs résistantes aux médicaments	412,000	Potentiel de marché de 1,7 milliard de dollars

Oric Pharmaceuticals, Inc. (ORIC) - Modèle d'entreprise: Structure des coûts

Frais de recherche et de développement

Pour l'exercice 2023, Oric Pharmaceuticals a déclaré des dépenses totales de R&D de 96,4 millions de dollars, ce qui représente un investissement important dans le développement de la thérapeutique en oncologie.

Exercice fiscal	Dépenses de R&D	Pourcentage d'augmentation
2022	81,2 millions de dollars	18.7%
2023	96,4 millions de dollars	18.7%

Investissements d'essais cliniques

ORIC a alloué 62,3 millions de dollars spécifiquement pour les activités d'essai cliniques en 2023, en se concentrant sur le développement de pipelines en oncologie.

• Essais de phase 1: 22,1 millions de dollars
• Essais de phase 2: 34,5 millions de dollars
• Études précliniques: 5,7 millions de dollars

Coûts de protection de la propriété intellectuelle

ORIC a dépensé 3,7 millions de dollars pour le dépôt, l'entretien et la protection juridique des brevets de la propriété intellectuelle en 2023.

Recrutement et rétention des talents scientifiques

Le total des dépenses de personnel pour les talents scientifiques a atteint 41,5 millions de dollars en 2023, avec une compensation moyenne de 285 000 $ par chercheur spécialisé.

Catégorie de personnel	Nombre d'employés	Compensation totale
Scientifiques supérieurs	45	18,2 millions de dollars
Associés de recherche	87	23,3 millions de dollars

Dépenses de conformité et d'essai réglementaires

Les coûts de conformité réglementaire pour ORIC ont totalisé 5,9 millions de dollars en 2023, couvrant les soumissions de la FDA, les tests externes et la documentation réglementaire.

• Frais de soumission de la FDA: 1,6 million de dollars
• Services de test externes: 2,8 millions de dollars
• Documentation de la conformité: 1,5 million de dollars

ORIC Pharmaceuticals, Inc. (ORIC) - Modèle d'entreprise: sources de revenus

Revenus potentiels de licence de médicament futurs

En 2023, les informations financières, ORIC Pharmaceuticals a des revenus de licence potentiels associés à leurs candidats en oncologie, spécifiquement pour ORIC-533 et ORIC-114.

Drogue	Valeur de licence potentielle	Étape de développement
ORIC-533	Jusqu'à 560 millions de dollars en paiements de jalons potentiels	Essais cliniques de phase 1/2
ORIC-114	Jusqu'à 475 millions de dollars en paiements de jalons potentiels	Développement préclinique

Subventions et financement de recherche

ORIC Pharmaceuticals a obtenu un financement de recherche à partir de diverses sources:

• Concessionnaires du National Cancer Institute (NCI): 2,3 millions de dollars en 2022
• Concessions de recherche sur l'innovation des petites entreprises (SBIR): environ 1,5 million de dollars par an

Accords de partenariat stratégique

ORIC a établi des partenariats stratégiques avec des sociétés pharmaceutiques:

Partenaire	Valeur de l'accord	Domaine de mise au point
Pfizer	Paiement initial de 50 millions de dollars	Recherche en oncologie de précision
Miserrer	Contrat de collaboration de 35 millions de dollars	Développement de la thérapie contre le cancer

Paiements de jalons potentiels de la recherche collaborative

Répartition potentielle des paiements de jalons:

• Paiements de jalons précliniques: jusqu'à 25 millions de dollars par programme
• Jalons de développement clinique: jusqu'à 100 millions de dollars par programme
• Jalons d'approbation réglementaire: jusqu'à 200 millions de dollars par programme

Ventes de produits pharmaceutiques futures

Potentiel de vente de produits pharmaceutiques projetés:

Produit	Potentiel de vente annuel estimé	Marché cible
ORIC-533	250 à 500 millions de dollars	Traitements tumoraux solides
ORIC-114	150 $ - 350 millions de dollars	Oncologie de précision

ORIC Pharmaceuticals, Inc. (ORIC) - Canvas Business Model: Value Propositions

ORIC Pharmaceuticals, Inc. focuses its value creation on developing treatments designed to address the core challenge of therapeutic resistance in oncology. This mission is supported by a focused clinical pipeline, evidenced by the company's financial prioritization, which included securing $244 million in financing during the second quarter of 2025, extending the cash runway into 2H 2028 from that point.

The company's value propositions are anchored in two lead clinical candidates, each designed with a differentiated approach to overcome resistance mechanisms:

• Overcoming therapeutic resistance in cancer (the core mission).
• ORIC-944: Potential best-in-class PRC2 inhibitor for mCRPC.
• Enozertinib: Brain-penetrant inhibitor with strong CNS activity in NSCLC.
• Differentiated mechanism of action targeting innate and acquired resistance.

ORIC-944: Potential best-in-class PRC2 inhibitor for mCRPC

ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, is positioned as a potential best-in-class agent for metastatic castration-resistant prostate cancer (mCRPC). The preliminary efficacy data from the ongoing Phase 1b trial in combination with androgen receptor (AR) inhibitors showed substantial clinical activity. The company expects to initiate its first Phase 3 trial for ORIC-944 in mCRPC in the 1H 2026. Goldman Sachs estimates peak sales for ORIC-944 at $2.6 billion.

Efficacy Metric (ORIC-944 + AR Inhibitor)	Response Rate	Number of Patients (n)
PSA50 Response Rate (as of May 2025)	59%	17
Confirmed PSA50 Response Rate (as of May 2025)	47%	17
PSA90 Response Rate (all confirmed, as of May 2025)	24%	17

The safety profile observed in this trial was compatible with long-term dosing, with the vast majority of adverse events being Grade 1 or 2. The most common treatment-related adverse event was diarrhea, occurring in 53% of patients (9/17) across all dose levels as of April 22, 2025.

Enozertinib: Brain-penetrant inhibitor with strong CNS activity in NSCLC

Enozertinib (ORIC-114) is a brain-penetrant inhibitor targeting EGFR exon 20, HER2 exon 20, and EGFR atypical mutations in non-small cell lung cancer (NSCLC). Its design specifically addresses the limitation of available therapies by aiming for high brain penetrance. Preliminary data from the Phase 1b trial in 1L EGFR PACC patients, using the selected dose of 80 mg QD oral enozertinib, showed compelling activity. The company reported a 100% intracranial Overall Response Rate (ORR) in patients with measurable CNS disease.

The preliminary systemic activity for these patients was 80% ORR. Furthermore, the ORR in median 3L EGFR PACC patients reached 36%, which is noted to exceed competitor benchmarks. As of the November 18, 2025 cutoff date, 60% of the 10 efficacy evaluable patients dosed with 80 mg QD had brain metastases at baseline, all of which were active and untreated.

Differentiated mechanism of action targeting innate and acquired resistance

ORIC Pharmaceuticals' value is rooted in developing agents that target the specific mechanisms driving resistance. For ORIC-944, preclinical data demonstrated synergistic activity and improved progression-free survival when combined with AR pathway inhibitors. For enozertinib, the profile is differentiated by its selectivity and brain penetration, which mitigates common off-target toxicities associated with many tyrosine kinase inhibitors (TKIs). The company is advancing both programs toward potential registrational studies, with ORIC-114 expected to begin in the latter half of 2025 and ORIC-944 in early 2026.

The company reported total operating expenses for Q3 2025 were $36.7 million, with Research & Development costs at $28.8 million.

ORIC Pharmaceuticals, Inc. (ORIC) - Canvas Business Model: Customer Relationships

You're managing a clinical-stage oncology pipeline, so your relationships with investigators and investors are everything right now. For ORIC Pharmaceuticals, Inc. (ORIC), these connections are highly structured, focusing on data dissemination and strategic alignment.

High-touch engagement with clinical investigators and sites is critical for advancing your pipeline candidates, ORIC-944 and enozertinib (ORIC-114). The engagement level is reflected in the trial execution data. For instance, as of the August 29, 2025 cutoff date for the enozertinib Phase 1b trial, 49 patients were dosed across the study cohorts, with 26 patients receiving 80 mg QD oral enozertinib and 23 patients receiving 120 mg QD. This level of patient enrollment requires close coordination with clinical sites. Furthermore, data from the ORIC-944 trial in metastatic castration-resistant prostate cancer (mCRPC) showed encouraging responses, with a 59% PSA50 response rate and a 24% PSA90 response rate as of the May 2025 cutoff dates. Favorable enrollment trends in the ORIC-944 trial also suggest strong investigator buy-in.

The company maintains active direct investor relations via conferences and webcasts to keep the financial community informed about these clinical milestones. Management actively participates in key industry events to discuss strategy and pipeline progress. Here's a look at the scheduled investor interactions in the latter half of 2025:

Conference Name	Date (2025)	Format/Activity
Citi's 2025 Biopharma Back to School Summit	September 3	Fireside Chat and One-on-one meetings
Wells Fargo Healthcare Conference	September 4	Fireside Chat and One-on-one meetings
Cantor Global Healthcare Conference	September 5	Fireside Chat and One-on-one meetings
Morgan Stanley 23rd Annual Global Healthcare Conference	September 9	One-on-one meetings
Baird 2025 Global Healthcare Conference	September 10	Fireside Chat
Guggenheim's 2nd Annual Healthcare Innovation Conference	November 11	Webcast available
Jefferies London Healthcare Conference	November 19	Webcast available
8th Annual Evercore Healthcare Conference	December 3	Fireside Chat and One-on-one meetings

Webcasts of these fireside chats are made available, and replays are accessible for 90 days following the event, ensuring broad stakeholder access.

Scientific communication through peer-reviewed publications and congresses validates the underlying science. ORIC Pharmaceuticals presented key data at the ESMO Asia Congress 2025 in December 2025. Specifically, data from a Phase 1b trial of enozertinib (ORIC-114) in previously treated NSCLC patients with HER2 exon 20 mutations were presented at a poster session. Furthermore, compelling preliminary data in 1L NSCLC patients with EGFR P-loop and alpha C-helix compressing (PACC) mutations were disclosed. Preclinical work also saw presentation time, with posters on ORIC-944 presented at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics in October 2025. The company also presented ORIC-944 data at the 2025 American Association for Cancer Research (AACR) Annual Meeting in April 2025.

The management of relationships with strategic pharma partners for combination trials is a core part of the development strategy, allowing ORIC Pharmaceuticals to maintain full economic ownership while leveraging partner resources. A key relationship is the clinical trial collaboration and supply agreement with Johnson & Johnson (J&J) to evaluate ORIC-114 in combination with subcutaneous amivantamab for the first-line treatment of NSCLC patients with EGFR exon 20 insertion mutations. The company also leverages strategic collaborations with Bayer. Initial data from this J&J combination trial, along with ORIC-114 monotherapy data in 1L EGFR atypical mutations, are expected in mid-2026. The ORIC-944 program also involves combination studies with AR inhibitors like apalutamide and darolutamide.

Finance: draft 13-week cash view by Friday.

ORIC Pharmaceuticals, Inc. (ORIC) - Canvas Business Model: Channels

The Channels block for ORIC Pharmaceuticals, Inc. centers on disseminating critical clinical progress and maintaining financial transparency with stakeholders while actively managing its global clinical footprint.

Global network of clinical trial sites in North America and Europe

ORIC Pharmaceuticals, Inc. utilizes a network of clinical trial sites to advance its lead candidates, ORIC-944 and enozertinib (ORIC-114). The company is currently enrolling studies across multiple indications, which necessitates a geographically distributed site network, primarily in North America and Europe, given the typical scope of US-headquartered biopharma trials.

• Currently enrolling Phase 1b study of ORIC-944 in prostate cancer with AR inhibitors.
• Currently enrolling Phase 1b/2 study of single-agent enozertinib in EGFR/HER2 mutated NSCLC.
• Currently enrolling Phase 1b study of enozertinib in combination with subcutaneous amivantamab in NSCLC with EGFR exon 20 mutations.

The operational focus is on advancing these programs, supported by $413.0M in cash, cash equivalents, and investments as of the third quarter of 2025. This financial position is projected to fund the operating plan into 2H 2028.

Investor Relations website for financial and pipeline updates

The primary digital channel for investor communication is the Investor Relations section of the corporate website, www.oricpharma.com. This channel delivers formal financial disclosures and pipeline milestones, such as the Q3 2025 financial results reported on November 13, 2025.

Here's a look at the recent financial and pipeline context delivered through this channel:

Metric/Update	Value/Date	Context
Cash, Cash Equivalents, and Investments (Q3 2025)	$413.0M	As of September 30, 2025
Projected Cash Runway	Into 2H 2028	Following strategic pipeline prioritization
Workforce Reduction	Approx. 20%	Streamlining operations to focus on lead programs
ORIC-944 Phase 3 Trial Initiation Target	1H 2026	For metastatic castration-resistant prostate cancer (mCRPC)
ORIC-114 Registrational Trial Initiation Target	2026	Focusing on first-line NSCLC settings

Scientific and medical conferences for data dissemination

Conferences serve as the crucial channel for disseminating primary clinical data to the scientific and medical community. ORIC Pharmaceuticals, Inc. actively presents at key industry events to build scientific credibility for its assets.

• Presented enozertinib (ORIC-114) data at the ESMO Asia Congress 2025 (December 5-7).
• Participated in the 8th Annual Evercore Healthcare Conference on November 24, 2025.
• Management participated in one-on-one meetings at the Guggenheim\'s 2nd Annual Healthcare Innovation Conference (November 11, 2025) and the Jefferies London Healthcare Conference (November 19, 2025).

The data presented at ESMO Asia 2025 included an Overall Response Rate (ORR) of 35% in the enozertinib 80 mg QD cohort for previously treated NSCLC patients with HER2 exon 20 mutations.

Future channel: Specialty pharmaceutical distributors upon commercialization

This channel is currently prospective, contingent upon successful progression through planned late-stage trials. The company is planning to initiate registrational trials for both lead programs in 2026. Upon potential regulatory approval, ORIC Pharmaceuticals, Inc. will need to establish relationships with specialty pharmaceutical distributors to manage the supply chain and market access for its targeted oncology therapies.

ORIC Pharmaceuticals, Inc. (ORIC) - Canvas Business Model: Customer Segments

The customer segments for ORIC Pharmaceuticals, Inc. (ORIC) are defined by the specific patient populations targeted by its clinical pipeline candidates, ORIC-944 and enozertinib (ORIC-114), as well as potential strategic partners.

Oncologists and hematologists treating advanced cancers are key decision-makers and prescribers. Their adoption is influenced by clinical trial results and the potential for best-in-class profiles. As of the third quarter ended September 30, 2025, ORIC Pharmaceuticals had a market capitalization of $1.2B, with a stock price of $12.38 as of November 5, 2025. The company reported cash, cash equivalents and investments totaling $327.7 million as of June 30, 2025. This financial position is expected to fund the operating plan into 2H 2028.

Patients with metastatic castration-resistant prostate cancer (mCRPC) are the target for ORIC-944, a PRC2 inhibitor being tested in combination with androgen receptor pathway inhibitors like apalutamide (ERLEADA) or darolutamide (NUBEQA). The global prostate cancer market is projected to reach $29.2 billion by 2035, with approximately 10% to 20% of all prostate cancers classified as castration-resistant.

Efficacy data from the ongoing Phase 1b trial of ORIC-944 in combination with AR inhibitors for mCRPC patients, with a cutoff date of September 22, 2025, demonstrates the potential value proposition for this segment:

Efficacy Endpoint (ORIC-944 Combination)	Response Rate	Confirmation Status
PSA50 Response Rate	55%	Confirmed in 40%
PSA90 Response Rate	20%	All confirmed

This data is based on patients previously treated with a median of three lines of prior therapy.

Patients with NSCLC having specific EGFR/HER2 exon 20 or atypical mutations are the focus for enozertinib (ORIC-114). The prevalence of these mutations defines the addressable patient pool:

• HER2 exon 20 insertion mutations: observed in approximately 1.5% of all NSCLC patients.
• Atypical EGFR mutations: observed in approximately 2.9% of all NSCLC patients.

For previously treated NSCLC patients with HER2 exon 20 mutations, data presented as of an August 29, 2025 cutoff showed activity:

Dose (Enozertinib QD)	Patients Dosed	Objective Response Rate (ORR)	Disease Control Rate (DCR)
80 mg	26	35% (26% confirmed)	100%
120 mg	23	Not explicitly stated as 35% for this group alone	Not explicitly stated as 100% for this group alone

Enrollment for the HER2 exon 20 mutation population is complete, with no further development planned in that specific group. The 80 mg QD dose was selected for potential Phase 3 development based on data across other EGFR exon 20 and atypical mutation populations. Approximately 47% of the HER2 exon 20 patients at baseline had brain metastases.

Large pharmaceutical companies for potential future licensing/M&A represent a segment for potential non-dilutive financing or commercialization partnerships. ORIC Pharmaceuticals established three strategic partnerships with major pharmaceutical companies as of February 2025. Following a strategic pipeline prioritization, the Company announced it will explore potential partnering of its preclinical programs.

Finance: draft 13-week cash view by Friday.

ORIC Pharmaceuticals, Inc. (ORIC) - Canvas Business Model: Cost Structure

You're looking at the core burn rate for ORIC Pharmaceuticals, Inc. (ORIC) as of late 2025, and honestly, it's what you expect for a clinical-stage biotech: it's almost entirely driven by science.

The Cost Structure for ORIC Pharmaceuticals, Inc. (ORIC) is overwhelmingly dominated by Research & Development (R&D) expenses, which is the engine fueling their pipeline advancement. For the third quarter of 2025, the Total Operating Expenses were reported at \$36.671 million. This figure reflects the necessary investment to push ORIC-944 and enozertinib through their respective clinical stages.

Here's a quick look at how that total operating spend broke down for the quarter ended September 30, 2025:

Expense Category	Q3 2025 Amount (in millions USD)
Total Operating Expenses	\$36.671
Research & Development (R&D) Expenses	\$28.8
General and Administrative (G&A) Expenses	\$7.9

Digging into that R&D spend, you see where the money is actually going to the bench and the bedside. The R&D expenses for the quarter were \$28.8 million. A significant portion of that external spend was dedicated to the enozertinib program, with \$9.0M specifically attributed to external R&D costs for enozertinib in Q3 2025. The internal R&D costs, which include personnel and stock-based compensation, were \$10.3 million for the quarter, and ORIC-944 manufacturing costs were \$5.6 million externally, plus \$3.8 million for preclinical/other external costs. It's all about program advancement, so you need to track those external costs closely.

General and Administrative (G&A) expenses were \$7.9 million in Q3 2025, a slight increase from the prior year, reflecting higher personnel and services costs as the company streamlined operations. Furthermore, this quarter included a specific, non-recurring cost related to that streamlining effort: a one-time charge of \$1.9 million recognized for termination benefits following the workforce reduction. This kind of opex friction is common when a company narrows its focus to lead programs.

You can see the key cost drivers clearly:

• R&D expenses were \$28.8 million for the quarter.
• External costs for enozertinib totaled \$9.0 million.
• G&A was \$7.9 million.
• A one-time charge of \$1.9 million hit the books.

Finance: draft 13-week cash view by Friday.

ORIC Pharmaceuticals, Inc. (ORIC) - Canvas Business Model: Revenue Streams

ORIC Pharmaceuticals, Inc. is currently operating in a pre-revenue phase, meaning product sales are not yet a source of income. For the quarter ended September 30, 2025, the reported Actual Revenue was N/A, which aligns with the reported net loss of $32.6 million for the last quarter.

The primary focus for future revenue generation is centered on the successful clinical progression and eventual commercialization of its two lead product candidates. The company is actively advancing these programs toward potential registrational studies, which is the critical step before generating sales revenue.

Future potential revenue streams are tied directly to these clinical assets:

• ORIC-944: An allosteric inhibitor of the polycomb repressive complex 2 (PRC2), being developed for prostate cancer.
• Enozertinib (ORIC-114): A brain-penetrant inhibitor targeting specific EGFR and HER2 mutations, being developed for multiple genetically defined cancers, including lung cancer.

ORIC Pharmaceuticals expects to report four clinical data readouts across both the ORIC-944 and enozertinib programs through mid-2026, with a potential initiation of registrational trials for both programs targeted in 2026. The World Health Organization has officially recognized 'enozertinib' as its generic name.

Potential milestone payments from strategic licensing or co-development deals represent another non-sales revenue component. While specific deal terms aren't public, the company's focus on advancing these programs to registrational studies suggests that achieving these key clinical milestones could trigger pre-agreed payments from any existing or future partners.

Interest income is derived from the significant balance of cash and investments held on the balance sheet. As of September 30, 2025, ORIC Pharmaceuticals reported cash, cash equivalents, and investments totaling approximately $413 million. This substantial balance is projected to fund the revised operating plan into the second half of 2028 (2H 2028) and beyond the anticipated primary endpoint readouts from the first Phase 3 trials.

Here's a quick look at the financial position supporting this runway:

Financial Metric	Amount (USD Millions)	Period End Date
Cash and Investments Balance	$413.0	September 30, 2025
Research & Development Expenses	$28.8	Three Months Ended September 30, 2025
Cash Runway Projection	Into 2H 2028	As of November 2025

The company has made a prudent decision to substantially reduce investment in discovery research to direct financial resources toward these lead clinical programs.